Position in GILD
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$686,784
-$5,599,917 QoQ
Shares Held
5,436
-87.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#1,239
of 2,266 holders
Holding Since
Sep 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Derivatives in GILD
reported options exposure · as of Jun 30, 2026CallValue
$23,360,266
CallShares
184,900
PutValue
$11,964,398
PutShares
94,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Alphadyne Asset Management LP holds $1,132,456 across 2 Drug Manufacturers - General names. GILD ranks #1 (60.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
This page
|
5,436 | $686,784 | |
| 2 | PFE |
Pfizer Inc
|
18,508 | $445,672 |
All Filings in GILD
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $686,784 | 5,436 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $23,360,266 | 184,900 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $11,964,398 | 94,700 | Put | Sole | 2026-08-14 | |
| 2026-03-31 | $6,286,701 | 45,108 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $19,609,359 | 140,700 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $26,354,867 | 189,100 | Put | Sole | 2026-05-15 | |
| 2025-12-31 | $12,298,548 | 100,200 | Call | Sole | 2026-02-17 | |
| 2025-12-31 | $12,998,166 | 105,900 | Put | Sole | 2026-02-17 | |
| 2023-09-30 | $1,206,534 | 16,100 | Put | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||